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http://dx.doi.org/10.1016/j.cell.2013.10.016When AIDS was first recognized in 1981,
health professionals were ill equipped to
address the emerging pandemic. Oppor-
tunistic infections were treated, and sup-
portive care was provided in accordance
with the regional availability of healthcare;
however, even after HIV was recognized
as the causative agent of AIDS, truly
effective therapy would not be available
for more than a decade. Prevention
methods were similarly insufficient, as
messages about safe sex and condoms
often provedweaker than human impulse.
But helplessness has now given way to
hope. Basic and clinical scientific ad-
vances have yielded powerful therapeutic
and preventive interventions. By the end
of 2012, 9.7 million HIV-infected individ-
uals worldwide were receiving antiretrovi-
ral therapy (ART), and some 4.2 million
deaths had been averted during the previ-
ous decade in low-income and middle-
income countries. These feats were
accomplished through the joint efforts of
the US President’s Emergency Plan for
AIDS Relief; the Global Fund to Fight
AIDS, Tuberculosis and Malaria (among
other multilateral and bilateral organiza-
tions); health practitioners in endemic
countries; and community activists world-
wide. Combination prevention methods
have been applied with striking results
(WHO, 2013). For example, programs
aimed at the prevention of mother-to-
child transmission have proven highly
successful (US Department of State,
2013). Voluntary male medical circumci-
sion for the prevention of HIV acquisition
shows considerable promise (Gray et al.,
2012). Pre-exposure antiretroviral pro-
phylaxis lowers the risk of infection,
particularly if adherence to treatment is
high (Okwundu et al., 2012). Treatment
of an HIV-infected individual with ART
benefits that person and substantially re-
duces the likelihood of transmitting HIV
to his or her uninfected sexual partner(Cohen et al., 2011); additionally, it can
significantly reduce community-level HIV
incidence (Granich et al., 2013). Research
into the social and behavioral factors gov-
erning acceptance and uptake of these
interventions will guide effective deploy-
ment. Thus, for the first time since AIDS
was recognized, the goal to control and
even end the HIV/AIDS pandemic has
become part of the global health dialog
(Folkers and Fauci, 2010).
Despite these accomplishments, there
is much unfinished business. While ex-
panding availability of existing interven-
tions, new prevention and treatment
methods must be developed. An HIV vac-
cine is a crucial goal for prevention, and
several strategies are being pursued.
Although an effective vaccine has proven
elusive so far, a trial (RV144) undertaken in
Thailand showed a modest 31% reduc-
tion in infection in people given the vac-
cine (Rerks-Ngarm et al., 2009). Tradition-
ally, induction of neutralizing antibodies
against the targeted pathogen is the hall-
mark of a successful vaccine. So far, HIV
vaccines, including the RV144 candidate,
have been unable to generate broadly
neutralizing antibodies or cytotoxic T cell
responses capable of preventing HIV
infection in human trials. In fact, natural
infection with HIV elicits detectable
broadly neutralizing antibodies in about
20% of infected individuals—a process
that takes 2 years or longer. On the basis
of this finding, several groups of investiga-
tors have pursued an alternative B cell
vaccine strategy: broadly neutralizing an-
tibodies derived from infected individuals
have been used to identify epitopes on
the HIV envelope trimer that could be
used as immunogens to induce broadly
reactive antibodies (Klein et al., 2013;
Hoot et al., 2013; Kwong et al., 2013).
This B cell pathway toward an HIV vac-
cine will likely need to be combined with
an additional strategy involving the induc-Cell 155,tion of T cells that enhance B-lymphocyte
responses, produce anti-HIV cytokines,
or provide cytolytic activity against HIV-
infected cells. Finally, harnessing the
innate immune response as part of a vac-
cine strategy is being actively pursued.
In addition to preventing HIV infection,
prevention and treatment of disease pro-
gression in the 35.3 million HIV-infected
people worldwide is an enormous chal-
lenge, which will require efficient delivery
of existing therapies and the discovery
of improved interventions. Where ART is
available, improved implementation will
need to address deficiencies in the care
continuum—the steps from diagnosis to
retention in care and successful treat-
ment. In some regions, discrimination,
stigma, and legal barriers impede the real-
ization of optimum care. These impedi-
ments must be addressed. Furthermore,
longer-acting therapies could improve
adherence to pre-exposure prophylaxis
and treatment. Understanding of co-in-
fections such as tuberculosis and hepati-
tis B and C; of chronic comorbidities,
including atherosclerosis, some cancers,
liver and kidney disease, and neurocogni-
tive problems; and of the aging process
are also crucial.
Finally, a cure for HIV infection is no
longer beyond the imagination, and
efforts are aimed at either eradication of
HIV in infected individuals or indefinite
control of viral replication in the absence
of ART, referred to as a functional cure
(Chun and Fauci, 2012). To realize the
potential of these efforts, along with those
directed at vaccine development and new
treatments, translation of concepts into
interventions will prove essential.
A range of highly effective HIV treat-
ment and prevention methods is avail-
able, and others are under intensive
investigation through basic and transla-
tional research. By combining effective
implementation of existing methods withNovember 7, 2013 ª2013 Elsevier Inc. 733
Figure 1. A Three-Pronged Strategy to Achieve an AIDS-free World, Defined as Very Few
New Infections and Minimum Morbidity and Premature Death from Existing Infectionsthe discovery and eventual introduction of
new interventions, achieving an AIDS-free
world is no longer an idealistic aspira-
tion—it is an achievable goal (Figure 1).
Editor’s Note
This Commentary is being published
simultaneously in Cell and The Lancet.
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